Navigation Links
AstraZeneca and Abbott End License Agreement for the Development of CERTRIAD
Date:12/22/2010

WILMINGTON, Del., Dec. 22, 2010 /PRNewswire/ -- AstraZeneca (NYSE: AZN) announced today that it has notified Abbott that it will discontinue the development of CERTRIAD™ (rosuvastatin calcium and fenofibric acid), which was being investigated for the treatment of mixed dyslipidemia. This means the co-development and license agreement with Abbott will end on January 22, 2011.  

A Complete Response Letter (CRL) for the CERTRIAD New Drug Application (NDA) was received from the U.S. Food and Drug Administration (FDA) on March 30, 2010.

The companies reached this decision after careful review and consideration of the CRL and the resulting regulatory delay, and have determined that the development of CERTRIAD is no longer commercially attractive.  

AstraZeneca will continue to focus on other development priorities both within and outside of the cardiovascular disease therapeutic area.

NOTES TO EDITORS:

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines.  As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009.  In the United States, AstraZeneca is a $14.8 billion healthcare business.   

For more information about AstraZeneca in the US or our AZ&Me™ Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363).


'/>"/>
SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
2. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
5. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
6. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
7. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
8. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
9. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
10. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
11. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... , May 31, 2016 Aloe ... in food, cosmetics and pharmaceuticals, with global volume to ... US$ 1.6 Bn. Demand for aloe vera ... and yogurts will continue its upward momentum in 2016 ... also boost positive sentiment on aloe vera, with wide-ranging ...
(Date:5/31/2016)... Israel , May 31, 2016 ... its proprietary plant-based rhCollagen technology for tissue repair products ... Chief Scientist of Israel,s Ministry ... 12 million development project for 2016. The Chief Scientist,s grant ... year,s authorized grant, which totaled NIS 4.7 million.  ...
(Date:5/31/2016)... , May 31, 2016 ... research report with comparative analysis of Asthma therapy at ... action (MoA), route of administration (RoA) and molecule type, ... releases. It also reviews key players involved in the ... and discontinued projects. Complete report on H1 ...
Breaking Medicine Technology:
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... More than ... Hep B United Philadelphia, and the Prevent Cancer Foundation held an event on National ... epidemic in the city of viral hepatitis, the leading cause of liver cancer. , ...
(Date:5/31/2016)... ... 2016 , ... St. Joseph Medical Center (SJMC) announced that ... enables physicians at SJMC’s two hospital campuses, downtown and in the Heights, to ... exchange. SJMC’s membership in the health information exchange underscores the hospital’s commitment to ...
(Date:5/31/2016)... ... May 31, 2016 , ... When MetLoop first demonstrated its ... something that contractors should have at their disposal on a daily basis. , ... Director of Contractor Programs. , As a result, Metloop and CertainTeed entered ...
(Date:5/31/2016)... ... May 31, 2016 , ... Spartan Bioscience ... enables unprecedented portability and convenience. , The Cube is exceptionally small—it takes up ... the Cube fits easily into any space, whether in a hospital, doctor’s office, ...
(Date:5/31/2016)... ... ... Like jewels in a crown, the multiple awards presented to Fayez Spa confirm ... day spa and one of Canada’s few accredited 5 Star Spas! , The ... spa services with hair and beauty services and has resulted in creating ...
Breaking Medicine News(10 mins):